Chronos Archive seal
The Human Record

Babe Didrikson Zaharias

Case HR-ML038 · Modern EHR teaching episode · Draft for review

Review summary

Historical dates
June 26, 1911 – September 27, 1956
Synthetic DOB
1984-06-26
Index visit
2026-03-16 at age 41
Synthetic MRN
HR-ML038-SYN

Teaching objective: Recognize early-onset rectal cancer in a fit woman of 41, below the screening age, whose rectal bleeding and change in bowel habit could be put down to hemorrhoids, and care for it on the NCCN rectal cancer guideline and the ASCO guidance on locally advanced rectal cancer: a digital rectal examination and prompt colonoscopy with biopsy; mismatch repair testing of every colorectal cancer; germline genetic testing because she is under 50; staging by pelvic MRI and CT, with CEA; a multidisciplinary tumor board; and, because the tumor is mismatch repair deficient, PD-1 blockade with dostarlimab and a watch-and-wait strategy after a clinical complete response, sparing her the abdominoperineal resection and permanent colostomy that a tumor this low would otherwise need. The episode also covers immune-related adverse events (hypothyroidism), iron deficiency anemia, sexual health and body image, return to elite sport, screening of first-degree relatives, the USPSTF screening age of 45, and survivorship care, set against her documented operation with a permanent colostomy in 1953 and her return to win a national championship afterwards.

Historical timeline

DateEventClaims
June 26, 1911Born in Port Arthur, Texas; the family moves to Beaumont in 1915.CLM-0001, CLM-0002
1932Wins two gold medals and a silver medal in track and field at the Los Angeles Olympic Games.CLM-0003
December 23, 1938Marries George Zaharias.CLM-0004
1950Voted Associated Press Woman Athlete of the Half-Century, a year after co-founding the LPGA; about this time she buys the Tampa Golf and Country Club and lives there.CLM-0005
End of 1952Extremely fatigued by the end of the golf season.CLM-0006
April 17, 1953Diagnosed with cancer in April 1953; operation including a colostomy in Beaumont.CLM-0007, CLM-0008
July 1954Wins the U.S. Women's Open by twelve strokes, 14 months after the operation.CLM-0009
1955The cancer returns; she re-enters John Sealy Hospital in Galveston in June and sets up a cancer fund with her husband in September.CLM-0010, CLM-0011
September 27, 1956Dies of cancer at John Sealy Hospital in Galveston at 45.CLM-0012

Evidence claims

D = documented, R = retrospective, S = synthetic.

GradeClaimCertaintySources
D Mildred Ella Didrikson was born in Port Arthur, Texas, on June 26, 1911, the sixth of seven children of the Norwegian immigrants Ole Nickolene and Hannah Marie (Olson) Didriksen; she later changed the spelling of her surname. In 1915 the family moved to Beaumont, Texas. confirmed Cayleff SE. Zaharias, Mildred Ella Didrikson [Babe] (Handbook of Texas Online) supports
Michals D, ed. Mildred "Babe" Didrikson Zaharias supports
HISTMED Master Roster v3 context
D Her birth year is given variously: she wrote 1914 on her application for the 1932 Olympics, and some sources, including a historical marker at her grave, give 1913, 1914 or 1915; her gravestone and baptismal certificate support 1911.
Explains why her age is given differently, including in her obituaries; 1911 is used.
confirmed Winters K. Zaharias, Babe Didrikson (Notable Sports Figures) supports
Zaharias, Babe Didrikson (1911-1956) (Women in World History: A Biographical Encyclopedia) supports
D At the 1932 Olympic Games in Los Angeles she won gold medals in the javelin and the 80-meter hurdles and a silver medal in the high jump, where her head-first technique was ruled a foul.
Anchors the modern social history: an elite athlete all her adult life.
confirmed Cayleff SE. Zaharias, Mildred Ella Didrikson [Babe] (Handbook of Texas Online) supports
Michals D, ed. Mildred "Babe" Didrikson Zaharias supports
D She met the professional wrestler George Zaharias at the 1938 Los Angeles Open, and they married on December 23, 1938; he became her manager.
History only; her husband is given no role in the modern episode.
confirmed Cayleff SE. Zaharias, Mildred Ella Didrikson [Babe] (Handbook of Texas Online) supports
Michals D, ed. Mildred "Babe" Didrikson Zaharias supports
D She took up golf in 1933, won 17 amateur tournaments in a row between 1943 and 1947, co-founded the Ladies Professional Golf Association in 1949, and was voted the Associated Press Woman Athlete of the Half-Century in 1950. About 1950 she and her husband bought the Tampa Golf and Country Club in Florida and moved into its converted clubhouse.
Anchors the modern social history: a professional golfer who lives at the golf club she owns in Tampa.
confirmed Michals D, ed. Mildred "Babe" Didrikson Zaharias supports
Winters K. Zaharias, Babe Didrikson (Notable Sports Figures) supports
The Life and Achievements of Babe Didrikson Zaharias supports
D By the end of the 1952 golf season she was feeling extremely fatigued.
The anchor for the modern presenting problem (fatigue, rectal bleeding and a change in bowel habit). One source only; no other symptom before the diagnosis was found in the sources read.
probable Winters K. Zaharias, Babe Didrikson (Notable Sports Figures) supports
D She was diagnosed with cancer in April 1953 and had an operation that included a colostomy on April 17, 1953, in Beaumont, Texas. She missed the 1953 U.S. Women's Open while she recovered.
The documented diagnosis and operation to which the modern diagnosis is linked. The colostomy was permanent; the modern episode avoids one.
confirmed Cayleff SE. Zaharias, Mildred Ella Didrikson [Babe] (Handbook of Texas Online) supports
The Life and Achievements of Babe Didrikson Zaharias supports
Winters K. Zaharias, Babe Didrikson (Notable Sports Figures) supports
Michals D, ed. Mildred "Babe" Didrikson Zaharias supports
1954 U.S. Women's Open; 1953 U.S. Women's Open supports
R The sources read call her cancer colon cancer and do not name the operation or give any pathology. That it was a low rectal cancer removed by abdominoperineal resection is a retrospective reading of the permanent colostomy, which was then the usual result of that operation; some popular accounts call it rectal cancer.
Retrospective. The modern episode uses a low rectal adenocarcinoma, which fits a permanent colostomy in 1953; this is a teaching choice, not a resolution of the historical question.
possible The Life and Achievements of Babe Didrikson Zaharias context
Zaharias, Babe Didrikson (1911-1956) (Women in World History: A Biographical Encyclopedia) context
1954 U.S. Women's Open; 1953 U.S. Women's Open context
D She was back in tournament competition 14 weeks after the operation, received the Ben Hogan Comeback Player of the Year award for 1954, and in 1954 won five tournaments, including the U.S. Women's Open, played on July 1 to 3 at Salem Country Club in Peabody, Massachusetts, which she won by twelve strokes.
Documented return to elite sport after the operation; the modern plan is built around her golf.
confirmed Zaharias, Babe Didrikson (1911-1956) (Women in World History: A Biographical Encyclopedia) supports
Cayleff SE. Zaharias, Mildred Ella Didrikson [Babe] (Handbook of Texas Online) supports
1954 U.S. Women's Open; 1953 U.S. Women's Open supports
D The cancer returned in 1955: back surgery that year found cancer near her sacrum, and in June 1955 she re-entered John Sealy Hospital at the University of Texas Medical Branch in Galveston, where treatment could not contain its spread.
Documented recurrence after the episode; history only.
probable Cayleff SE. Zaharias, Mildred Ella Didrikson [Babe] (Handbook of Texas Online) supports
1954 U.S. Women's Open; 1953 U.S. Women's Open supports
The Life and Achievements of Babe Didrikson Zaharias supports
D She was one of the first public figures to speak openly about her cancer, and raised money and awareness for cancer education and research; in September 1955 she and her husband set up the Babe Didrikson Zaharias Fund, which financed a tumor clinic at the University of Texas Medical Branch. The American Cancer Society gave her a certificate of appreciation.
Her documented openness about cancer anchors the modern plan's attention to screening of relatives and public education.
confirmed The Life and Achievements of Babe Didrikson Zaharias supports
Zaharias, Babe Didrikson (1911-1956) (Women in World History: A Biographical Encyclopedia) supports
Cayleff SE. Zaharias, Mildred Ella Didrikson [Babe] (Handbook of Texas Online) supports
D She died of cancer at John Sealy Hospital in Galveston, Texas, on September 27, 1956, at 45, and was buried in Beaumont. One reference work gives September 26, and the contemporary New York Times report gave her age as 42.
The documented death from cancer, to which the synthetic diagnosis is linked. History only, stated without detail.
confirmed Cayleff SE. Zaharias, Mildred Ella Didrikson [Babe] (Handbook of Texas Online) supports
The Life and Achievements of Babe Didrikson Zaharias supports
Zaharias, Babe Didrikson (1911-1956) (Women in World History: A Biographical Encyclopedia) supports
Winters K. Zaharias, Babe Didrikson (Notable Sports Figures) supports

Modern synthetic problem list

GradeProblemClinical statusVerificationPlacementHistorical claims
S Bright red blood with bowel movements for about three months, with narrower stools, urgency, a feeling of incomplete emptying, and a firm, ulcerated mass felt on the back wall of the lower rectum at about 5 cm from the anal verge: a rectal cancer must be confirmed or excluded. Colonoscopy with biopsy booked this week resolved confirmed active CLM-0006
S Iron deficiency anemia from chronic rectal blood loss: hemoglobin 11.0 g/dL, MCV 77 fL, ferritin 9 ng/mL, with tiredness active confirmed active CLM-0006
S Adenocarcinoma of the low rectum, mismatch repair deficient (loss of MSH2 and MSH6; microsatellite instability high), cT3bN1M0 (stage IIIB) on pelvic MRI, lower edge 4 cm from the anal verge and about 1 cm above the anorectal junction, mesorectal fascia clear, no extramural venous invasion; CEA 5.8 ng/mL; synthetic modern detail linked to her documented cancer, whose site the sources do not record exactly active confirmed both_with_link CLM-0007, CLM-0012, CLM-0008
S Acute viral upper respiratory infection with cough and sore throat, a week before cycle 4 of dostarlimab; oxygen saturation and chest X-ray normal, so immune-related pneumonitis is unlikely; rapid influenza and COVID-19 tests negative; resolved resolved confirmed active CLM-0007, CLM-0012
S Immune-related primary hypothyroidism from dostarlimab, grade 2: tiredness and cold hands, TSH 12.6 mIU/L and free T4 0.6 ng/dL after four doses, following a mild TSH rise four weeks earlier; dostarlimab continued active confirmed active CLM-0007, CLM-0012

Synthetic outcome measures

GradeDateMeasureResultCoding
S 2026-03-16 Hemoglobin [Mass/volume] in Blood 11 g/dL (low)
Reference 12-15.5 g/dL
http://loinc.org · 718-7
S 2026-03-16 MCV [Entitic mean volume] in Red Blood Cells by Automated count 77 fL (low)
Reference 80-100 fL
http://loinc.org · 787-2
S 2026-03-16 Leukocytes [#/volume] in Blood by Automated count 6.8 10*3/uL
Reference 4-11 10*3/uL
http://loinc.org · 6690-2
S 2026-03-16 Platelets [#/volume] in Blood by Automated count 412 10*3/uL (high)
Reference 150-400 10*3/uL
http://loinc.org · 777-3
S 2026-03-16 Ferritin [Mass/volume] in Serum or Plasma 9 ng/mL (low)
Reference 15-150 ng/mL
http://loinc.org · 2276-4
S 2026-03-16 Sodium [Moles/volume] in Serum or Plasma 139 mmol/L
Reference 135-145 mmol/L
http://loinc.org · 2951-2
S 2026-03-16 Potassium [Moles/volume] in Serum or Plasma 4.1 mmol/L
Reference 3.5-5.1 mmol/L
http://loinc.org · 2823-3
S 2026-03-16 Creatinine [Mass/volume] in Serum or Plasma 0.78 mg/dL
Reference 0.59-1.04 mg/dL
http://loinc.org · 2160-0
S 2026-03-16 Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 98 mL/min/1.73 m²
Reference >=60 mL/min/1.73 m²
http://loinc.org · 98979-8
S 2026-03-16 Glucose [Mass/volume] in Serum or Plasma 88 mg/dL
Reference 70-99 mg/dL
http://loinc.org · 2345-7
S 2026-03-16 Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 18 U/L
Reference 7-35 U/L
http://loinc.org · 1742-6
S 2026-03-16 Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 21 U/L
Reference 8-35 U/L
http://loinc.org · 1920-8
S 2026-03-16 Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma 72 U/L
Reference 35-104 U/L
http://loinc.org · 6768-6
S 2026-03-16 Bilirubin.total [Mass/volume] in Serum or Plasma 0.6 mg/dL
Reference 0.1-1.2 mg/dL
http://loinc.org · 1975-2
S 2026-03-16 Albumin [Mass/volume] in Serum or Plasma 4.3 g/dL
Reference 3.5-5 g/dL
http://loinc.org · 1751-7
S 2026-03-16 Carcinoembryonic Ag [Mass/volume] in Serum or Plasma 5.8 ng/mL (high)
Reference Up to 3.0 ng/mL in non-smokers
http://loinc.org · 2039-6
S 2026-03-16 Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 1 http://loinc.org · 55758-7
S 2026-03-30 Hemoglobin [Mass/volume] in Blood 11.1 g/dL (low)
Reference 12-15.5 g/dL
http://loinc.org · 718-7
S 2026-03-30 Leukocytes [#/volume] in Blood by Automated count 6.5 10*3/uL
Reference 4-11 10*3/uL
http://loinc.org · 6690-2
S 2026-03-30 Platelets [#/volume] in Blood by Automated count 405 10*3/uL (high)
Reference 150-400 10*3/uL
http://loinc.org · 777-3
S 2026-03-30 Creatinine [Mass/volume] in Serum or Plasma 0.76 mg/dL
Reference 0.59-1.04 mg/dL
http://loinc.org · 2160-0
S 2026-03-30 Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 101 mL/min/1.73 m²
Reference >=60 mL/min/1.73 m²
http://loinc.org · 98979-8
S 2026-03-30 Glucose [Mass/volume] in Serum or Plasma 90 mg/dL
Reference 70-99 mg/dL
http://loinc.org · 2345-7
S 2026-03-30 Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 17 U/L
Reference 7-35 U/L
http://loinc.org · 1742-6
S 2026-03-30 Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 20 U/L
Reference 8-35 U/L
http://loinc.org · 1920-8
S 2026-03-30 Thyrotropin [Units/volume] in Serum or Plasma 1.9 mIU/L
Reference 0.45-4.5 mIU/L
http://loinc.org · 3016-3
S 2026-03-30 Thyroxine (T4) free [Mass/volume] in Serum or Plasma 1.2 ng/dL
Reference 0.8-1.8 ng/dL
http://loinc.org · 3024-7
S 2026-03-30 Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 6 http://loinc.org · 44261-6
S 2026-03-30 Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] 7 http://loinc.org · 70274-6
S 2026-04-27 Hemoglobin [Mass/volume] in Blood 12.1 g/dL
Reference 12-15.5 g/dL
http://loinc.org · 718-7
S 2026-04-27 MCV [Entitic mean volume] in Red Blood Cells by Automated count 80 fL
Reference 80-100 fL
http://loinc.org · 787-2
S 2026-04-27 Leukocytes [#/volume] in Blood by Automated count 6.2 10*3/uL
Reference 4-11 10*3/uL
http://loinc.org · 6690-2
S 2026-04-27 Platelets [#/volume] in Blood by Automated count 352 10*3/uL
Reference 150-400 10*3/uL
http://loinc.org · 777-3
S 2026-04-27 Creatinine [Mass/volume] in Serum or Plasma 0.74 mg/dL
Reference 0.59-1.04 mg/dL
http://loinc.org · 2160-0
S 2026-04-27 Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 104 mL/min/1.73 m²
Reference >=60 mL/min/1.73 m²
http://loinc.org · 98979-8
S 2026-04-27 Glucose [Mass/volume] in Serum or Plasma 92 mg/dL
Reference 70-99 mg/dL
http://loinc.org · 2345-7
S 2026-04-27 Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 22 U/L
Reference 7-35 U/L
http://loinc.org · 1742-6
S 2026-04-27 Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 24 U/L
Reference 8-35 U/L
http://loinc.org · 1920-8
S 2026-04-27 Thyrotropin [Units/volume] in Serum or Plasma 2.2 mIU/L
Reference 0.45-4.5 mIU/L
http://loinc.org · 3016-3
S 2026-04-27 Thyroxine (T4) free [Mass/volume] in Serum or Plasma 1.2 ng/dL
Reference 0.8-1.8 ng/dL
http://loinc.org · 3024-7
S 2026-04-27 Carcinoembryonic Ag [Mass/volume] in Serum or Plasma 3.4 ng/mL (high)
Reference Up to 3.0 ng/mL in non-smokers
http://loinc.org · 2039-6
S 2026-04-27 Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 4 http://loinc.org · 44261-6
S 2026-06-01 Hemoglobin [Mass/volume] in Blood 12.6 g/dL
Reference 12-15.5 g/dL
http://loinc.org · 718-7
S 2026-06-01 Leukocytes [#/volume] in Blood by Automated count 9.4 10*3/uL
Reference 4-11 10*3/uL
http://loinc.org · 6690-2
S 2026-06-01 Platelets [#/volume] in Blood by Automated count 290 10*3/uL
Reference 150-400 10*3/uL
http://loinc.org · 777-3
S 2026-06-01 Thyrotropin [Units/volume] in Serum or Plasma 5.8 mIU/L (high)
Reference 0.45-4.5 mIU/L
http://loinc.org · 3016-3
S 2026-06-01 Thyroxine (T4) free [Mass/volume] in Serum or Plasma 1 ng/dL
Reference 0.8-1.8 ng/dL
http://loinc.org · 3024-7
S 2026-06-29 Hemoglobin [Mass/volume] in Blood 13 g/dL
Reference 12-15.5 g/dL
http://loinc.org · 718-7
S 2026-06-29 Leukocytes [#/volume] in Blood by Automated count 6 10*3/uL
Reference 4-11 10*3/uL
http://loinc.org · 6690-2
S 2026-06-29 Platelets [#/volume] in Blood by Automated count 268 10*3/uL
Reference 150-400 10*3/uL
http://loinc.org · 777-3
S 2026-06-29 Sodium [Moles/volume] in Serum or Plasma 140 mmol/L
Reference 135-145 mmol/L
http://loinc.org · 2951-2
S 2026-06-29 Potassium [Moles/volume] in Serum or Plasma 4.2 mmol/L
Reference 3.5-5.1 mmol/L
http://loinc.org · 2823-3
S 2026-06-29 Creatinine [Mass/volume] in Serum or Plasma 0.75 mg/dL
Reference 0.59-1.04 mg/dL
http://loinc.org · 2160-0
S 2026-06-29 Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 102 mL/min/1.73 m²
Reference >=60 mL/min/1.73 m²
http://loinc.org · 98979-8
S 2026-06-29 Glucose [Mass/volume] in Serum or Plasma 89 mg/dL
Reference 70-99 mg/dL
http://loinc.org · 2345-7
S 2026-06-29 Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 20 U/L
Reference 7-35 U/L
http://loinc.org · 1742-6
S 2026-06-29 Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 22 U/L
Reference 8-35 U/L
http://loinc.org · 1920-8
S 2026-06-29 Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma 70 U/L
Reference 35-104 U/L
http://loinc.org · 6768-6
S 2026-06-29 Bilirubin.total [Mass/volume] in Serum or Plasma 0.5 mg/dL
Reference 0.1-1.2 mg/dL
http://loinc.org · 1975-2
S 2026-06-29 Albumin [Mass/volume] in Serum or Plasma 4.4 g/dL
Reference 3.5-5 g/dL
http://loinc.org · 1751-7
S 2026-06-29 Thyrotropin [Units/volume] in Serum or Plasma 12.6 mIU/L (high)
Reference 0.45-4.5 mIU/L
http://loinc.org · 3016-3
S 2026-06-29 Thyroxine (T4) free [Mass/volume] in Serum or Plasma 0.6 ng/dL (low)
Reference 0.8-1.8 ng/dL
http://loinc.org · 3024-7
S 2026-06-29 Carcinoembryonic Ag [Mass/volume] in Serum or Plasma 2.1 ng/mL
Reference Up to 3.0 ng/mL in non-smokers
http://loinc.org · 2039-6
S 2026-06-29 Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 3 http://loinc.org · 44261-6
S 2026-08-10 Thyrotropin [Units/volume] in Serum or Plasma 3.1 mIU/L
Reference 0.45-4.5 mIU/L
http://loinc.org · 3016-3
S 2026-08-10 Thyroxine (T4) free [Mass/volume] in Serum or Plasma 1.1 ng/dL
Reference 0.8-1.8 ng/dL
http://loinc.org · 3024-7
S 2026-08-10 Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 2 http://loinc.org · 44261-6
S 2026-10-05 Hemoglobin [Mass/volume] in Blood 13.4 g/dL
Reference 12-15.5 g/dL
http://loinc.org · 718-7
S 2026-10-05 MCV [Entitic mean volume] in Red Blood Cells by Automated count 86 fL
Reference 80-100 fL
http://loinc.org · 787-2
S 2026-10-05 Leukocytes [#/volume] in Blood by Automated count 6.1 10*3/uL
Reference 4-11 10*3/uL
http://loinc.org · 6690-2
S 2026-10-05 Platelets [#/volume] in Blood by Automated count 255 10*3/uL
Reference 150-400 10*3/uL
http://loinc.org · 777-3
S 2026-10-05 Creatinine [Mass/volume] in Serum or Plasma 0.77 mg/dL
Reference 0.59-1.04 mg/dL
http://loinc.org · 2160-0
S 2026-10-05 Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 99 mL/min/1.73 m²
Reference >=60 mL/min/1.73 m²
http://loinc.org · 98979-8
S 2026-10-05 Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 19 U/L
Reference 7-35 U/L
http://loinc.org · 1742-6
S 2026-10-05 Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 21 U/L
Reference 8-35 U/L
http://loinc.org · 1920-8
S 2026-10-05 Ferritin [Mass/volume] in Serum or Plasma 41 ng/mL
Reference 15-150 ng/mL
http://loinc.org · 2276-4
S 2026-10-05 Thyrotropin [Units/volume] in Serum or Plasma 2.4 mIU/L
Reference 0.45-4.5 mIU/L
http://loinc.org · 3016-3
S 2026-10-05 Thyroxine (T4) free [Mass/volume] in Serum or Plasma 1.2 ng/dL
Reference 0.8-1.8 ng/dL
http://loinc.org · 3024-7
S 2026-10-05 Carcinoembryonic Ag [Mass/volume] in Serum or Plasma 1.6 ng/mL
Reference Up to 3.0 ng/mL in non-smokers
http://loinc.org · 2039-6
S 2026-10-05 Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 2 http://loinc.org · 44261-6
S 2026-10-05 Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] 3 http://loinc.org · 70274-6

Synthetic vital signs

DateMeasureResultLOINCGrade
2026-03-16Body height168 cm8302-2S
2026-03-16Body weight62.8 kg29463-7S
2026-03-16Body mass index (BMI) [Ratio]22.3 kg/m239156-5S
2026-03-16Systolic blood pressure112 mm[Hg]8480-6S
2026-03-16Diastolic blood pressure70 mm[Hg]8462-4S
2026-03-16Heart rate86 /min8867-4S
2026-03-16Respiratory rate14 /min9279-1S
2026-03-16Body temperature36.7 Cel8310-5S
2026-03-16Oxygen saturation in Arterial blood by Pulse oximetry99 %59408-5S
2026-03-30Body height168 cm8302-2S
2026-03-30Body weight62.6 kg29463-7S
2026-03-30Body mass index (BMI) [Ratio]22.2 kg/m239156-5S
2026-03-30Systolic blood pressure116 mm[Hg]8480-6S
2026-03-30Diastolic blood pressure72 mm[Hg]8462-4S
2026-03-30Heart rate80 /min8867-4S
2026-03-30Respiratory rate14 /min9279-1S
2026-03-30Body temperature36.6 Cel8310-5S
2026-03-30Oxygen saturation in Arterial blood by Pulse oximetry99 %59408-5S
2026-04-27Body height168 cm8302-2S
2026-04-27Body weight63.2 kg29463-7S
2026-04-27Body mass index (BMI) [Ratio]22.4 kg/m239156-5S
2026-04-27Systolic blood pressure110 mm[Hg]8480-6S
2026-04-27Diastolic blood pressure68 mm[Hg]8462-4S
2026-04-27Heart rate70 /min8867-4S
2026-04-27Respiratory rate14 /min9279-1S
2026-04-27Body temperature36.6 Cel8310-5S
2026-04-27Oxygen saturation in Arterial blood by Pulse oximetry99 %59408-5S
2026-06-29Body height168 cm8302-2S
2026-06-29Body weight63.8 kg29463-7S
2026-06-29Body mass index (BMI) [Ratio]22.6 kg/m239156-5S
2026-06-29Systolic blood pressure114 mm[Hg]8480-6S
2026-06-29Diastolic blood pressure72 mm[Hg]8462-4S
2026-06-29Heart rate60 /min8867-4S
2026-06-29Respiratory rate14 /min9279-1S
2026-06-29Body temperature36.4 Cel8310-5S
2026-06-29Oxygen saturation in Arterial blood by Pulse oximetry99 %59408-5S
2026-10-05Body height168 cm8302-2S
2026-10-05Body weight63.4 kg29463-7S
2026-10-05Body mass index (BMI) [Ratio]22.5 kg/m239156-5S
2026-10-05Systolic blood pressure112 mm[Hg]8480-6S
2026-10-05Diastolic blood pressure70 mm[Hg]8462-4S
2026-10-05Heart rate64 /min8867-4S
2026-10-05Respiratory rate14 /min9279-1S
2026-10-05Body temperature36.6 Cel8310-5S
2026-10-05Oxygen saturation in Arterial blood by Pulse oximetry99 %59408-5S
2026-06-01Body height168 cm8302-2S
2026-06-01Body weight63 kg29463-7S
2026-06-01Body mass index (BMI) [Ratio]22.3 kg/m239156-5S
2026-06-01Systolic blood pressure114 mm[Hg]8480-6S
2026-06-01Diastolic blood pressure70 mm[Hg]8462-4S
2026-06-01Heart rate88 /min8867-4S
2026-06-01Respiratory rate16 /min9279-1S
2026-06-01Body temperature37.9 Cel8310-5S
2026-06-01Oxygen saturation in Arterial blood by Pulse oximetry98 %59408-5S
2026-08-10Body height168 cm8302-2S
2026-08-10Body weight63.6 kg29463-7S
2026-08-10Body mass index (BMI) [Ratio]22.5 kg/m239156-5S
2026-08-10Systolic blood pressure112 mm[Hg]8480-6S
2026-08-10Diastolic blood pressure68 mm[Hg]8462-4S
2026-08-10Heart rate62 /min8867-4S
2026-08-10Respiratory rate14 /min9279-1S
2026-08-10Body temperature36.5 Cel8310-5S
2026-08-10Oxygen saturation in Arterial blood by Pulse oximetry99 %59408-5S

Social, functional, and mental status

Social history

Functional status

Mental status

Allergies and medications

Allergies

Medications

Procedures and immunizations

Procedures

Immunizations

Past medical history

True biography with historical dates; not part of the synthetic care timeline.

Family history

No family medical history is documented in the logged sources. Family history of real relatives is never synthesized.

Care-plan goals

GoalTarget dateStatusOutcome
Colonoscopy within one week, staging within two weeks, and a tumor board plan before treatment2026-03-30completedColonoscopy in three days, MRI and CT within nine days, tumor board in eleven days, consultation at two weeks
Germline genetic testing with counseling, and an explanation of the mismatch repair deficiency, within four weeks of diagnosis2026-04-27completedGermline panel negative; two somatic MSH2 variants in the tumor explain the deficiency
Clinical complete response after six months of dostarlimab, with the rectum and sphincter preserved2026-10-05completedClinical complete response on MRI, endoscopy and examination after nine doses; watch-and-wait begun
Hemoglobin of 12 g/dL or more and ferritin above 30 ng/mL2026-10-05completedHemoglobin 13.4 g/dL and ferritin 41 ng/mL
Back to tournament golf during treatment2026-06-29completedPlaying 18 holes and entered in a club competition by the fourth visit
TSH within the reference range on thyroid replacement2026-08-10completedTSH 3.1 mIU/L six weeks after levothyroxine began
PHQ-9 below 10 throughout treatment2026-10-05completedPHQ-9 between 2 and 6

Interventions

InterventionStatusGuideline
Medical oncology (gastrointestinal) consultation within two weeks, with colorectal surgery, to review the colonoscopy and any biopsy with her and plan staging and treatment if cancer is foundcompletedGL-NCCN-RECT-2026, GL-ASCO-LARC-2024
Urgent work-up of rectal bleeding with a change in bowel habit and a rectal mass in a woman under 50: colonoscopy with biopsy within days, with mismatch repair testing of any cancer; blood count, ferritin, chemistry and CEA; if cancer is confirmed, rectal-protocol MRI of the pelvis and CT of the chest, abdomen and pelvis; return at once for heavy bleeding, fainting or inability to pass stoolcompletedGL-NCCN-RECT-2026, GL-USPSTF-CRC-2021
Oral iron for iron deficiency anemia from blood loss: ferrous sulfate 325 mg on alternate days, a blood count about four weeks after starting, ferritin at about three months, and iron continued for three months after the hemoglobin is normalcompletedGL-CMID-2026
Germline multigene panel after genetic counseling, because she is under 50 and the tumor is mismatch repair deficient; tumor sequencing for somatic MMR variants if the germline panel is negative; colonoscopy for her first-degree relatives every five years from age 40, or 10 years before the age of her diagnosis if earlier, with Lynch syndrome surveillance only if a germline variant is foundcompletedGL-ASCO-GERM-2024, GL-NCCN-RECT-2026, GL-USMSTF-2017
Dostarlimab 500 mg intravenously every three weeks for nine doses (six months), with pelvic MRI, flexible sigmoidoscopy and digital rectal examination about every three months; blood count, kidney and liver tests and glucose before each dose and TSH with free T4 every six weeks; teaching about immune-related adverse events with a 24-hour line; hepatitis B, hepatitis C and HIV screening and a pregnancy test first; contraception continued during treatment and for four months aftercompletedGL-NCCN-RECT-2026, GL-ASCO-LARC-2024, GL-CERCEK-2022, GL-CERCEK-2025, GL-ASCO-IRAE-2021, GL-ASCO-HBV-2020
If the response is incomplete: chemoradiation and total mesorectal excision, as reviewed with the colorectal surgeon, with stoma site marking and teaching by a wound-ostomy nurse before any operation; fertility and sexual function counseling before any pelvic radiationcompletedGL-NCCN-RECT-2026, GL-ASCO-LARC-2024, GL-ASCO-FERT-2018
Levothyroxine for immune-related hypothyroidism, with TSH and free T4 six weeks after starting and every six weeks while on PD-1 blockade; dostarlimab continuedcompletedGL-ASCO-IRAE-2021, GL-CMID-2026
Watch-and-wait after a clinical complete response: digital rectal examination and flexible sigmoidoscopy every three to four months and pelvic MRI every six months for two years, CEA every three to six months, CT of the chest, abdomen and pelvis every six to twelve months, colonoscopy at one year, and a written survivorship care plan; surgery at once for any regrowthcompletedGL-NCCN-RECT-2026, GL-CMID-2026, GL-CERCEK-2025
Distress and depression screening at each visit; plain explanations with written information; attention to sexual health and body image and to her golf, with an exercise plan she sets; she decides who is told and who receives each notecompletedGL-USPSTF-DEP-2023, GL-ASCO-EX-2022

Planned encounters

Supporting documents

C-CDA note documents

Each link opens a readable copy; the XML beside it is the exchange file.

Sources

IDSourcePublisherType
SRC-0001 Cayleff SE. Zaharias, Mildred Ella Didrikson [Babe] (Handbook of Texas Online) Texas State Historical Association other
SRC-0002 Michals D, ed. Mildred "Babe" Didrikson Zaharias National Women's History Museum other
SRC-0003 Zaharias, Babe Didrikson (1911-1956) (Women in World History: A Biographical Encyclopedia) Encyclopedia.com (Gale) other
SRC-0004 Winters K. Zaharias, Babe Didrikson (Notable Sports Figures) Encyclopedia.com (Gale) other
SRC-0005 The Life and Achievements of Babe Didrikson Zaharias Babe Didrikson Zaharias Foundation other
SRC-0006 1954 U.S. Women's Open; 1953 U.S. Women's Open Wikipedia other
SRC-0007 HISTMED Master Roster v3 The Human Record project other

Review status

ReviewStatusNotes
schema validationnot_startedRun scripts/build.ps1 -Conformance.
clinical reviewnot_startedAwaiting clinician review; check the MRI staging of a low rectal tumor, the choice of dostarlimab alone for mismatch repair-deficient locally advanced disease, the restaging schedule and the definition of clinical complete response, the reading of loss of MSH2 and MSH6 with a negative germline panel and two somatic MSH2 variants, the management of immune-related hypothyroidism without holding treatment, and the watch-and-wait surveillance intervals.
provenance reviewnot_startedShe died in 1956; the recent-death rule does not apply. Claims rest on the Handbook of Texas (by her biographer Susan Cayleff), the National Women's History Museum, two Gale reference entries, the Babe Didrikson Zaharias Foundation and Wikipedia. The site of her cancer and the operation are recorded as R because the sources call it colon cancer and name no operation; everything clinical is synthetic.
safe messaging reviewnot_startedNo mental health or substance claim is made; mood screens are synthetic and below the threshold for a safety assessment. Her death is recorded once, without detail. No relative, companion or historical physician is given a role in the modern episode; her husband appears only in the documented history, and her close companion Betty Dodd is not used.

Comments and corrections

Sign in with GitHub to comment on this record. To report a specific error, ideally with a source, use the feedback form; each report becomes a tracked issue.

Comments appear on the online version of this page.